Aouabdi Sihem, Aboalola Doaa, Zakari Samer, Alwafi Suliman, Nedjadi Taoufik, Alsiary Rawiah
King Abdullah International Medical Research Center, Jeddah, 21423, Saudi Arabia.
King Saud Bin Abdulaziz University for Health Sciences, Jeddah, 21423, Saudi Arabia.
Future Sci OA. 2024 May 20;10(1):FSO924. doi: 10.2144/fsoa-2023-0179. eCollection 2024.
SARS-CoV-2 causes COVID-19. COVID-19 has led to severe clinical illnesses and an unprecedented death toll. The virus induces immune inflammatory responses specifically cytokine storm in lungs. Several published reports indicated that pregnant females are less likely to develop severe symptoms compared with non-pregnant. Putative protective role of maternal blood circulating fetal mesenchymal stem cells (MSCs) has emerged and have been put forward as an explanation to alleviated symptoms. MSCs with immune-modulatory, anti-inflammatory and anti-viral roles, hold great potential for the treatment of COVID-19. MSCs could be an alternative to treat infections resulting from the SARS-CoV-2 and potential future outbreaks. This review focuses on the MSCs putative protective roles against COVID-19 in pregnant females.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引发新型冠状病毒肺炎（COVID-19）。COVID-19已导致严重的临床疾病和前所未有的死亡人数。该病毒在肺部引发免疫炎症反应，特别是细胞因子风暴。一些已发表的报告表明，与未怀孕女性相比，怀孕女性出现严重症状的可能性较小。母体血液循环中的胎儿间充质干细胞（MSCs）的假定保护作用已显现，并被提出作为症状减轻的一种解释。具有免疫调节、抗炎和抗病毒作用的MSCs在治疗COVID-19方面具有巨大潜力。MSCs可能是治疗SARS-CoV-2感染及未来潜在疫情爆发的一种替代方法。本综述重点关注MSCs对怀孕女性COVID-19的假定保护作用。
